After Cowen & Co. and Barclays gave Alnylam Pharma (NASDAQ: ALNY) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Alan Carr maintained a Buy rating on Alnylam Pharma today and set a price target of $135. The company’s shares closed last Monday at $80.69.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 0.6% and a 41.4% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $125, implying a 51.3% upside from current levels. In a report issued on August 26, Piper Jaffray also reiterated a Buy rating on the stock with a $142 price target.
See today’s analyst top recommended stocks >>
Based on Alnylam Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $219 million. In comparison, last year the company had a GAAP net loss of $164 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.
